With the scaling limitations of current line probe and fluorogenic PCR systems, the new PCR array technology is expected to deliver more cost-effective infectious agent panel testing by providing a level of multiplexing and genetic information only available with microarray technologies. Akonni ™s first test based on the PCR array technology will be for the detection and subtyping of influenzas A and B. Starting from PCR-ready material extracted from swabs or nasopharyngeal aspirates using Akonni TruTip Extraction Kits, the test will deliver sub-typing results in less than 2 hours and with limits of detection equivalent to those of real-time PCR systems.

The recent H1N1 influenza pandemic, and fears of future H5N1 influenza pandemics, is driving development of more rapid and comprehensive sub-typing technologies for surveillance and diagnostic applications, explains Dr. George Rudy, Chief Medical Officer of Akonni Biosystems. Dr. Rudy adds, Four drugs have recently been approved by the US Food and Drug Administration (FDA) for the treatment of influenza, but the success of treatment depends on their early administration and may be related to the infecting strain.

akonni/